Is AbbVie Stock Too Cheap to Ignore at Today's Price?

Core Viewpoint - AbbVie remains attractively valued despite recent challenges, with potential for market-beating returns over the next five years [2] Valuation Metrics - AbbVie trades at 16.8 times forward earnings, lower than the healthcare sector average of 18.3 and the S&P 500 average of 22.6 [4] - The price/earnings-to-growth (PEG ratio) of 0.43 indicates that AbbVie is undervalued [4] Key Financial Data - Current stock price is $224.14 with a market cap of $398 billion [5] - The stock has a 52-week range of $164.39 to $244.81 and a gross margin of 69.68% [6] Growth Drivers - AbbVie has a diverse product lineup in neuroscience, oncology, and immunology, with Skyrizi and Rinvoq as key growth drivers [7] - These products are approved for multiple indications and will maintain patent exclusivity for at least the next five years [8] Future Prospects - AbbVie is expected to expand its product lineup through new approvals from its extensive pipeline [9] - The company will not face major patent cliffs through the end of the 2020s, supporting consistent revenue and earnings growth [8] Dividend Information - AbbVie is recognized as a Dividend King, having increased its payouts for 54 consecutive years [10] - The company's strong dividend program makes it an attractive option for income-seeking investors [11]